News

No catch-all drug works to treat irritable bowel syndrome with constipation. But as the Mayo Clinic expert explains, enough unique options exist to tailor care better than ever.

In this interview, Dr. Yu explains several important pieces of information regarding atopic dermatitis that he believes clinicians should be aware of.

The FDA has issued a Class I recall for some of Fresenius Medical Care's hemodialysis machines due to potential exposure to toxic compounds, affecting eight specific models from the 2008 Series.

Induction treatment with guselkumab resulted in a rapid onset of efficacy, beginning at week 1 and increasing over time to week 12, for patients with refractory moderately to severely active ulcerative colitis.

Patients with UC and Crohn's disease showed higher drug levels and good acceptance when switching from intravitreal to subcutaneous infliximab.

The FDA has granted 510(k) Clearance to the Omnipod 5 app for iPhone, making Insulet Corporation the first to offer a tubeless AID system with smartphone control.

Etrasimod demonstrated rapid and significant symptomatic improvement, with differences compared to placebo evident as early as 2 days after initiation of treatment in patients with ulcerative colitis.

Study author Uma Mahadevan, MD, discusses her team's findings suggesting the concern of IBD flare risk in pregnant women receiving aspirin to prevent preeclampsia is unwarranted.

Completion of prescription app-based cognitive behavioral therapy using Mahana IBS significantly reduced symptom severity and perceived stress for patients with irritable bowel syndrome.

Results from the 104-week extension study were presented at ACG 2023, demonstrating mirikizumab’s favorable safety and efficacy profiles.

Investigator Brian E. Lacy, MD, PhD discusses new post hoc analysis that he hopes will provided clearer expectations for timing of benefit with tenapanor.

Experts recommended the early use of anti-TNF therapy for patients with ulcerative colitis and Crohn disease, offering further input regarding the introduction, optimization, and maintenance of the treatment for patients with IBD.

Announced by Milestone Pharmaceuticals on October 24, 2023, the New Drug Application includes positive results on etripamil from the pivotal phase 3 RAPID trial.

In his ‘Early Dermatology Practice Pearls’ presentation, Dr. Song described tips for dermatologists. In this interview segment, he continues this discussion.

Findings from the phase 1 study informed the clinical development program for GP40141 as a biosimilar treatment for ITP, demonstrating pharmacodynamic similarity to reference romiplostim.

SB16, a denosumab biosimilar, demonstrated pharmacokinetic and pharmacodynamic comparability with reference denosumab in a phase 1 trial in healthy male adults.

Samsung Bioepis gains FDA interchangeability designation for its ranibizumab (Lucentis) biosimilar, ranibizumab-nuna (Byooviz), in the treatment of wAMD, macular edema following RVO, and mCMV

Advanced therapies for inflammatory bowel disease, namely small molecules and biologic therapies, did not increase the risk of a major adverse cardiovascular event or venous thromboembolism.

New research highlights the potential health risks associated with using smokeless tobacco, including anemia, hypertension, and chronic kidney disease.

Dr. Song spoke in this segment of his interview on several more insightful elements from his presentation titled ‘Early Dermatology Practice Pearls.’

Consumption of fruit and vegetables was found to be protective while consuming sweet snacks and candy along with supercenters and warehouse clubs as a primary food source were determined to be risk factors for early onset colorectal cancer mortality.

In a new study, upper endoscopy identified the cause of iron deficiency anemia in more than 70% of children.

Investigator Jiten P. Kothadia, MD, discusses the advent of a predictive score for alcohol relapse risk in patients with alcohol liver disease who received a liver transplant in the last year.

The 15 mg dose of tirzepatide was the most efficacious GLP-1 agonist for obesity management in patients without diabetes in a systemic review of data from MEDLINE and Embase databases.

In this interview segment, Dr. Song provided several unique viewpoints presented in his conference talk ‘Early Dermatology Practice Pearls.’

Presented at ACG 2023, findings from a retrospective cohort analysis revealed patients with ALD diagnosed with and prescribed at least 1 medication for alcohol use disorder had a decreased risk of mortality.

A large pediatric study suggests the diagnostic marker is both reliable and practical with high sensitivity and acceptable specificity for identifying iron deficiency and iron deficiency anemia.

Patients with plaque psoriasis, including in intertriginous areas and genitalia, experienced rapid improvement when treated with tapinarof cream 1%, offering an effective and well-tolerated nonsteroidal option for this condition.